---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-127507"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:57:18.513939+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Passage Bio reports promising Phase 1/2 data for PBFT02 in FTD-GRN; shifts strategy to adult neurodegenerative diseases

## Summary
- Dose 1 of PBFT02 achieved 3.6-6.6-fold increase in CSF PGRN at day 30, reaching supraphysiologic levels of 10.7-17.3 ng/mL.
- PBFT02 was generally well-tolerated with enhanced steroid regimen; no serious AEs in patients 2 and 3.
- Company to focus on PBFT02 in FTD-GRN, FTD-C9orf72, ALS, and Alzheimer's; seeking partnerships for pediatric programs.
- Expects to initiate dosing of Cohort 2 in 1H 2024 and report full 6-month data from Cohort 1 in 2H 2024.
- Estimates FTD-GRN prevalence at ~18,000 patients in US and Europe; exploring PBFT02 in larger indications.

## SEC filing metadata
- accession: 0001104659-23-127507
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000110465923127507/0001104659-23-127507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000110465923127507/tm2332555d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-127507
- JSON: https://secwatch.observer/filing/0001104659-23-127507.json
- Plain text: https://secwatch.observer/filing/0001104659-23-127507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.